Fintel reports that on April 17, 2025, BMO Capital upgraded their outlook for Trex (NYSE:TREX) from Market Perform to ...

BMO Capital Markets analyst Brian Pitz noted in a report that Google Network "is a lower-margin business relative to Search and YouTube," and that the company pays out to partners most of the ad ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Google illegally acted to preserve “monopoly power” in the digital ad-tech business, a federal judge ruled Thursday. It’s the ...

BMO Capital lowered the firm’s price target on CSX (CSX) to $35 from $36 but keeps an Outperform rating on the shares. The company’s Q1 ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

BMO Capital analyst Ketan Mamtora upgraded Trex Company (TREX) to Outperform from Market Perform with an unchanged price target of $72. The ...

The Bank of Canada on Wednesday held its key policy rate at 2.75%, its first pause after seven consecutive cuts, and said it ...

Tariff-driven volatility has redefined what's considered a "normal" day of bond-market trading, with traders contemplating "a wider scope of conceivable outcomes" as the global trade war unfolds, said ...

Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...